ライフサイエンスコーパス: sulfoximine

1 ield S,S-dimethyl-N-[(phenylmethoxy)carbonyl]sulfoximine.

2 on of glutamate to glutamine with methionine sulfoximine.

3 sgenic plants were abrogated by l-buthionine sulfoximine.

4 eatment with homocysteic acid and buthionine sulfoximine.

5 cted even after extended incubation with the sulfoximine.

6 , N-acetyl-l-cysteine, or d,l-buthionine-S,R-sulfoximine.

7 spite further depletion of GSH by buthionine sulfoximine.

8 mM) with or without GSH ester or buthionine sulfoximine.

9 ione synthetase inhibitor L-buthionine-(S,R)-sulfoximine.

10 subcutaneous administration of L-buthionine sulfoximine.

11 hibition of GSH synthesis with dl-buthionine sulfoximine.

12 t is inactivated by cystamine and buthionine sulfoximine.

13 e, glycine, phosphinothricin, and methionine sulfoximine.

14 ing effects of GSH depletion with buthionine sulfoximine.

15 tamylcysteine synthesis inhibitor buthionine sulfoximine.

16 bition by glutamine, glycine, and methionine sulfoximine.

17 inhibition of GSH biosynthesis by buthionine sulfoximine.

18 inhibition by glutamine, AMP, and methionine sulfoximine.

19 lity and gives several unprecedented N-azine sulfoximines.

20 GSH, cystamine, and transition state analog sulfoximines.

21 odobenzene directly converts sulfoxides into sulfoximines.

22 hilic substitution of azine N-oxides with NH-sulfoximines.

23 tions results in the formation of NH-S-alkyl sulfoximines.

24 d cultures of vSMCs with DL-buthionine-(S,R)-sulfoximine (0.1 mM), a depletor of cellular glutathione

25 ing groups including pyrrolidine amide, azo, sulfoximine, 1-pyrazole, and 1,2,3-triazole functionalit

26 on a gram scale allowed using the recovered sulfoximine (+)-1j in an asymmetric synthesis of FXa inh

27 Specifically, 24-(S)-NH phenyl sulfoximine 3a is an extremely potent CYP24 inhibitor (I

28 agine depletion via the ASNS inhibitor amino sulfoximine 5 (AS5) or asparaginase inhibited mouse and

29 ic acid (an inhibitor of GST-Pi), buthionine sulfoximine (a glutathione synthesis inhibitor), MK571 (

30 Treating tolerant mice with buthionine sulfoximine, a gamma-GCS inhibitor, eliminates resistanc

31 In normal islets, methionine sulfoximine, a glutamine synthetase inhibitor, suppresse

32 utralizing antibody (Ab) and by L-buthionine-sulfoximine, a GSH-depleting agent.

33 oxicity can be blocked by l-buthionine-(S,R)-sulfoximine, a specific inhibitor of glutamate-cysteine

34 17 in solution containing l-buthionine-(S,R)-sulfoximine, a specific inhibitor of GSH biosynthesis.

35 e glutathione synthesis inhibitor buthionine sulfoximine all cause oxidative injury to immature neuro

36 We found that this sulfoximine also inhibited AS-B, effectively irreversibl

37 amma-glutamylcysteine synthetase, buthionine sulfoximine, also decreased intracellular glutathione le

38 of NFI activity in vivo, we used buthionine sulfoximine, an agent that inhibits GSH synthesis, and N

39 okine production was inhibited by buthionine sulfoximine, an inhibitor of GCL.

40 Treatment of MCF-7 lines with buthionine sulfoximine, an inhibitor of glutathione synthesis, norm

41 esistant to the toxicity of buthionine-(S,R)-sulfoximine, an inhibitor of glutathione synthesis, than

42 , dogs were treated for 48 h with buthionine sulfoximine, an inhibitor of glutathione synthesis.

43 Treatment with buthionine sulfoximine, an inhibitor of GSH synthesis, also sensiti

44 A dozen 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxy

45 B3 cells pretreated with 10 mM DL-buthionine sulfoximine and 0.5 mM acivicin were used in GSH uptake

46 Hepatocytes were cultured with buthionine sulfoximine and 1,3-bis(chloroethyl)-1-nitrosourea (BCNU

47 increased up to 80% with combined buthionine sulfoximine and arsenic treatments, suggesting the enhan

48 Both buthionine sulfoximine and BCNU inhibited the induction of iNOS mRN

49 As with other GCL, buthionine sulfoximine and cystamine inactivate the Arabidopsis enz

50 kout/muscle) and pharmacological (methionine sulfoximine and dexamethasone) approaches to modulate GS

51 athione by treatment with L-buthionine-(S,R) sulfoximine and diethyl maleate, revealed no changes in

52 the glutathione-depleting agents buthionine sulfoximine and diethylmaleate were more potent in deple

53 ificantly reduced by the toxins L-methionine sulfoximine and fluoroacetate, which reduce glutamine co

54 e using the glutamate analogues l-methionine sulfoximine and l-methionine sulfone as substrates, with

55 5 +/- 43 and 610 +/- 23 s-1 for l-methionine sulfoximine and l-methionine sulfone, respectively.

56 Among them, sulfoximine and pyridinyl derivatives 24 and 29 possesse

57 with the GSH synthesis inhibitor buthionine sulfoximine, and aminonicotinamide (6-ANAM), an inhibito

58 tathione-depleting agent, L-buthionine-[S,R]-sulfoximine, and attenuated in cells pretreated with an

59 hylcytosine in cells treated with buthionine sulfoximine, and in mice depleted for the major antioxid

60 Aminotriazole, L-buthionine sulfoximine, and sodium azide partly abrogated the RGC r

61 sulfoxides, sulfinamides, N-sulfinyl ureas, sulfoximines, and some related S-chiral derivatives.

62 New sulfoximine- and phenanthrene-based photochemical precur

63 Mechanisms for the formation of the sulfoximine are presented as well as the product charact

64 As sulfoximines are analogues of sulfones where one of the

65 Sulfoximines are of considerable interest for incorporat

66 cysteine synthetase (gammaGCS) by buthionine sulfoximine augmented the increase in islet peroxide and

67 Sulfoximines bearing Boc and Cbz groups are stable to fu

68 H synthesis in a Glu (10 mM) plus buthionine-sulfoximine (BSO) (0.2 mM)-treated group, indicating tha

69 anced toxicity in the presence of buthionine sulfoximine (BSO) and attenuation of toxicity with exoge

70 on of GSH and Trx metabolism with buthionine sulfoximine (BSO) and auranofin (AUR), respectively, ind

71 es have identified nifurtimox and buthionine sulfoximine (BSO) as effective agents in children with n

72 hereas glutathione depletion with buthionine sulfoximine (BSO) augmented them.

73 nontoxic concentration of D,L-buthionine-S,R-sulfoximine (BSO) caused about 80-88% reduction in cellu

74 ressing cells by treatment with l-buthionine sulfoximine (BSO) causes decreased cell viability.

75 h 0.2 mmol/L diamide and 1 mmol/L buthionine sulfoximine (BSO) decreased GSH levels and increased the

76 dl-buthionine-[S, R]-sulfoximine (BSO) decreased intracellular GSH level, but

77 atment of AREc32 cells with l-buthionine-S,R-sulfoximine (BSO) did not influence basal levels of luci

78 d then were treated with DL-buthionine-(S,R)-sulfoximine (BSO) for an additional 24 hours.

79 l-Buthionine-S-sulfoximine (BSO) is a mechanism-based inhibitor of GCL

80 Glutathione (GSH) depletion by buthioninine sulfoximine (BSO) is being explored clinically as a mean

81 study, we examined the effect of buthionine sulfoximine (BSO) on mutation frequency and the formatio

82 eversible inhibitor of gammaGCS L-buthionine sulfoximine (BSO) reduced intracellular GSH levels in P.

83 Depletion of GSH by buthionine sulfoximine (BSO) restores the sensitivity of resistant

84 eduction of glutathione levels by buthionine sulfoximine (BSO) significantly enhanced the activity of

85 -D-glucose exposure using l-buthionine-[S,R]-sulfoximine (BSO) significantly enhanced the cytotoxic e

86 7, the cells were treated with L-buthionine sulfoximine (BSO) to deplete glutathione stores.

87 increased after treatment with L-buthionine sulfoximine (BSO) to lower GSH levels.

88 ed cytoenhancement, using L-buthionine-[S,R]-sulfoximine (BSO) to reduce cellular glutathione levels

89 ath caused by depletion of GSH by buthionine sulfoximine (BSO) was increased in mE10 and mE27 cells a

90 O(3) alone or in combination with buthionine sulfoximine (BSO) was studied in NB4, U937, Namalwa, and

91 GC-5 cells treated with glutamate/buthionine sulfoximine (BSO) were determined by RGC density analysi

92 eating uninfected astrocytes with buthionine sulfoximine (BSO), a glutathione synthesis inhibitor, or

93 ats were treated with: (1) L-buthionine(S,R)-sulfoximine (BSO), a specific inhibitor of gamma-glutamy

94 Treatment of cells with buthionine sulfoximine (BSO), an enzyme-activated inhibitor of gamm

95 Buthionine sulfoximine (BSO), an inhibitor of glutathione (GSH) syn

96 a glutathione-depleting agent, or buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis

97 Buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis

98 ced hearing loss by using l-buthionine-[S,R]-sulfoximine (BSO), an inhibitor of GSH synthesis, and 2-

99 l-Buthionine-S,R-sulfoximine (BSO), an inhibitor of GSH synthesis, marked

100 L-buthionine-S,R-sulfoximine (BSO), an inhibitor of GSH synthesis, was us

101 iving T cells and is abrogated by buthionine sulfoximine (BSO), an inhibitor of GSH synthesis.

102 when GSH synthesis was blocked by buthionine sulfoximine (BSO), an inhibitor of the enzyme required f

103 d tap water (vehicle) and 30 mM L-buthionine sulfoximine (BSO), an oxidant, with and without 1 mM tem

104 to date are rapidly inhibited by buthionine sulfoximine (BSO), most reports indicate that bacterial

105 s with diethyl maleate (DEM), D,L-buthionine sulfoximine (BSO), or tert-butylhydroquinone (TBH).

106 of glutathione synthesis, l-buthionine-[S,R]-sulfoximine (BSO), sensitized FaDu cells to the cytotoxi

107 ion by 18 hours pretreatment with buthionine sulfoximine (BSO), which depletes GSH by blocking its bi

108 E47 cells against AA toxicity or buthionine sulfoximine (BSO)-dependent toxicity.

109 osed to either L-glutamic acid or buthionine sulfoximine (BSO).

110 y exposing BPAE cells to dl-buthionine-[S,R]-sulfoximine (BSO).

111 igational chemotherapeutic agent buthionione sulfoximine (BSO).

112 ed by treating the cells with buthionine S,R-sulfoximine (BSO); 1-chloro, 2,4-dinitrobenzene (CDNB);

113 ulating redox homeostasis using l-buthionine-sulfoximine (BSO, glutathione synthesis inhibitor) and a

114 inhibitor buthionine sulfoximine (buthionine sulfoximine [BSO], 30 mmol/L) in drinking water for 2 wk

115 he glutathione synthase inhibitor buthionine sulfoximine (buthionine sulfoximine [BSO], 30 mmol/L) in

116 tal-free method for the synthesis of N-azine sulfoximines by the nucleophilic substitution of azine N

117 The inhibition of GS by methionine sulfoximine can be explained by the same mechanism.

118 Both enantiomers of the sulfoximines can be obtained with excellent ee values (u

119 Combined BaP/DL-buthionine-(S, R)-sulfoximine challenge was cytotoxic to the cells and inh

120 nversely, the GSH-depleting agent buthionine sulfoximine completely abolished the protective effects

121 cess elaboration was blocked by L-buthionine sulfoximine, consistent with mediation by an antioxidant

122 The reusable sulfoximine directing-group-assisted Ru(II)-catalyzed ch

123 enerators menadione, paraquat, or buthionine sulfoximine down-regulates c-FLIP long (c-FLIP(L)) prote

124 biting glutathione synthesis with buthionine-sulfoximine dramatically increased red blood cell sickli

125 trachlorobiphenyl, dexamethasone, buthionine sulfoximine, ethacrynic acid, or N-acetylcysteine pretre

126 ragine synthesis could be inactivated by the sulfoximine; free enzyme was unaffected even after exten

127 Pretreatment of HeLa cells with buthionine sulfoximine greatly potentiated the inactivation of NFI

128 nd methyllithium afforded replacement of the sulfoximine group by phenyl and methyl, respectively.

129 ion units containing sulfoxide, sulfone, and sulfoximine groups at C4 unveils an enhancement in bindi

130 s was inhibited by treatment with buthionine sulfoximine, GSH levels rapidly declined in E47 cells bu

131 eover, glutathione depletion with buthionine sulfoximine had no effect on MX transport or sensitivity

132 The interest in fluorinated sulfoximines has rapidly increased over the past twenty

133 x with one of these substrates (l-methionine sulfoximine) has been solved, revealing the mode of its

134 d allows the synthesis of substituted cyclic sulfoximines in high yields with complete stereocontrol,

135 lfinimines provides access to complex chiral sulfoximines in only two steps from commercially availab

136 esent the specific properties of fluorinated sulfoximines (including important bioactivities) and des

137 We show that nontoxic doses of l-buthionine sulfoximine increase the selectivity of organo-Os comple

138 reased, whereas the Gcl inhibitor buthionine sulfoximine increased DomA toxicity.

139 Pretreatment with L-buthionine sulfoximine increased SFN-induced ARE expression signifi

140 e by treatment of Hepa cells with buthionine sulfoximine increased the inducer potencies of several i

141 etion of intracellular GSH by D,L-buthionine sulfoximine increased the intracellular accumulation of

142 omyocytes, Rac1 activation with l-buthionine sulfoximine increased; Rac1 inhibition with NSC23766 dec

143 utathione) in A(L) cells with buthionine S-R-sulfoximine increases the mutagenic potential of arsenit

144 ione using N-acetylcysteine and L-buthionine-sulfoximine indicate that changes in glutathione levels

145 Neither Gln nor l-methionine sulfoximine-induced ammonium accumulation were effective

146 glutamate-, homocysteine-, and l-buthionine sulfoximine-induced toxicity.

147 Methionine sulfoximine inhibition of glucose stimulated insulin sec

148 e sulfinic acid interaction with AS-B or the sulfoximine interaction with AS-A, only AS-B productivel

149 elanthamidine, by transformation of a cyclic sulfoximine into a pyrroline, is also disclosed.

150 A convenient synthesis of N-protected sulfoximines is achieved, under mild conditions, by rhod

151 dine 2-carboxylates to unusual chiral cyclic sulfoximines is described herein.

152 esis of a variety of chiral sulfilimines and sulfoximines is described.

153 have shown that 10 microM L-buthionine-[S,R]-sulfoximine (L-BSO), an inhibitor of gamma-glutamylcyste

154 hione (GSH)-depleting compound, L-buthionine sulfoximine (L-BSO), exhibited enhanced sensitivity to D

155 the GSH synthesis inhibitor L-buthionine-S,R-sulfoximine (L-BSO).

156 bition of glutamine synthetase by methionine sulfoximine led to a substantial reduction in putrescine

157 ctivity by ATG and glutathione by buthionine sulfoximine led to overoxidation of Trx1 and loss of HeL

158 Depleting the GSH pool using buthionine sulfoximine limits fly survival, thus confirming that en

159 MK571, PSC833, and buthionine sulfoximine markedly increased cellular arsenic accumula

160 vity of glutamine synthetase with methionine-sulfoximine (MSO) and examined ammonia levels, brain wat

161 berculosis, the GS inhibitor L-methionine-SR-sulfoximine (MSO) protected the animals against weight l

162 imately 28 days) microinfusion of methionine sulfoximine (MSO: 0.625 to 2.5 microg/h) unilaterally in

163 mine synthesis in astrocytes with methionine sulfoximine (MSO; 1.5 mM) had no effect on miniature IPS

164 m reporters: nitrogen starvation, methionine sulfoximine (Msx) addition, nitrogen limitation, rapamyc

165 ed forms of methionine, including methionine sulfoximine (MSX) and methionine sulfone (MSO).

166 e glutamine synthetase inhibitor, methionine sulfoximine (MSX), although eliciting the same outcomes

167 ition, we studied the effect of L-methionine sulfoximine (MSX), an inhibitor of NH4+ assimilation by

168 as stabilized by phosphorylated L-methionine sulfoximine (MSX), fixing the enzyme in the transition s

169 tabolite repression-sensitive and methionine sulfoximine (Msx)-responsive) regulatory pathways.

170 r those treated with rapamycin or methionine sulfoximine (Msx).

171 treatment, and strong response to methionine sulfoximine (Msx, a glutamine synthetase inhibitor).

172 ) confirms that BSO is phosphorylated on the sulfoximine nitrogen to generate the inhibitory species

173 ither by the addition of DL-buthionine-(S,R)-sulfoximine or by removal of L-cystine from the culture

174 llular glutathione depletion with buthionine sulfoximine or energy depletion using 2-deoxy-D-glucose/

175 ion of glutathione synthesis with buthionine sulfoximine or inhibition of glutathione reductase activ

176 esolution of the resulting ketones by either sulfoximine or mandelate acetal technology has been appl

177 al inhibition of TOR signaling by methionine sulfoximine or rapamycin also increased CLS.

178 bitor of glutathione synthesis (L-buthionine-sulfoximine) or glutathione reductase (1,3-bis(2-chloroe

179 analogs N-methyl-D-aspartate and methionine sulfoximine, or by hyperbaric oxygen, are prevented by D

180 hibitor of glutathione synthesis, buthionine sulfoximine, or by the precursor of cysteine, O-acetylse

181 eatment of HeLa cells with 2 mm l-buthionine sulfoximine promoted the formation of ox-HSF1 and blocke

182 method may facilitate the preparation of NH-sulfoximines providing improved (global) deprotection st

183 The inhibitor L-methionine-S-sulfoximine rapidly inactivated purified M. tuberculosis

184 of pathogenic mycobacteria, L-methionine- S-sulfoximine rapidly inhibited extracellular glutamine sy

185 Treatment with l-buthionine-(S,R)-sulfoximine reduced glutathione content by 99% and preve

186 glutathione by pretreatment with buthionine sulfoximine rendered cells more susceptible to G2/M arre

187 Glutathione depletion by dl-buthionine-(S,R)-sulfoximine rendered hepatocytes susceptible to AEA-medi

188 A sulfoximine reported recently by Koizumi et al. as a com

189 ggravated by N-acetylcysteine and buthionine sulfoximine, respectively.

190 s of sulfoxides and sulfones, sulfimides and sulfoximines, respectively, are important compounds in a

191 glutathione synthetase inhibitor buthionine sulfoximine resulted in more rapid injury by glucose dep

192 e GSH synthesis inhibitor, L-buthionine-(SR)-sulfoximine, resulted in a time-dependent depletion of G

193 ar antioxidant, glutathione, with buthionine sulfoximine significantly increased B[a]P-mediated induc

194 uous GSH infusion, treatment with buthionine sulfoximine starting day - 2 decreased sinusoidal endoth

195 pared, differing not only at the stereogenic sulfoximine stereocenter but also at the A-ring.

196 e of glutamine was inhibited by l-methionine sulfoximine, suggesting a role for pita in protecting gl

197 nd intracellular GSH depletion by buthionine sulfoximine, suggesting that GSH transport is active and

198 r treatment of cells with L-buthionine-(S,R)-sulfoximine to deplete glutathione, selenoprotein H-over

199 rdingly, glutathione depletion by buthionine sulfoximine together with restoration of p53 activity re

200 eover, in contrast to AA, l-buthionine-(S,R)-sulfoximine toxicity is not prevented by plasmid Nrf2 pr

201 ted cells from both glutamate and buthionine sulfoximine toxicity.

202 tics were studied in acivicin and buthionine sulfoximine-treated HLE-B3 cells in NaCl medium in the c

203 ncreases from approximately 7% in methionine sulfoximine-treated mice to approximately 500% in dexame

204 sickling in the sickle kidney: in buthionine-sulfoximine-treated sickle mice, red blood cell sickling

205 Buthionine sulfoximine treatment resulted in a 24% reduction in can

206 y enhanced after GSH depletion by buthionine sulfoximine treatment.

207 depleting the glutathione pool by buthionine sulfoximine treatment.

208 N-allyl-, and N-benzyl-substituted S-alkenyl sulfoximines under appropriate conditions results in the

209 The N-aroyl sulfoximine undergoes annulation with diphenylacetylene,

210 ast, depletion of GSH by L-buthionine (S, R)-sulfoximine up-regulated the above described signaling c

211 emperatures during N-arylation of the simple sulfoximine used in this study.

212 mental drugs, i.e., auranofin and buthionine sulfoximine, was able to reduce the viral reservoir, eli

213 Although these sulfoximines were not active transcriptionally and were

214 activation; whereas TNFalpha or l-buthionine sulfoximine, which depletes GSH, further enhanced it.

215 less than 15% of basal levels) by buthionine sulfoximine, which does not directly modify Keap1, is al

216 transfer is developed for the preparation of sulfoximines, which are emerging as valuable motifs for

217 An efficient kinetic resolution of sulfoximines with enals was realized using chiral N-hete

218 Treatment of NH-sulfoximines with pseudocyclic benziodoxole triflate res